Replies to post #134655 on Biotech Values

[DewDiligence]

From a manpower standpoint, PFE’s Tofacitinib could be hitting the US market at just the right time. PFE is already scaling back US promotion of Enbrel in advance of AMGN’s re-acquiring the full US and Canadian rights to Enbrel in Oct 2013:

http://online.wsj.com/article/BT-CO-20120418-717671.html